BCL2 and diffuse large B-cell lymphoma: Our study showed that coexpression of BCL2 and MYC had a significantly worse outcome in HBsAg-positive DLBCL patients, while high expression of Ki-67 proliferation index, BCL2, MYC, and p53 did not affect prognosis in HBsAg-positive DLBCL patients.